Learn about the impact Gout has on patients and healthcare in our interview with noted rheumatologist, Dr. N. Lawrence Edwards 

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout and non-alcoholic steatohepatitis (NASH) for which there are no effective treatments.

Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is poised to enter global Phase 3 trials in 2022. Another compound, ABP-6016, has demonstrated safety and efficacy in preclinical trials for NASH, which is projected to become the most common cause of liver disease.

Latest News from Atom Bioscience

03 December, 2024
Atom Therapeutics and China Medical System Holdings Enter Exclusive Commercialization Agreement for Lingdolinurad (ABP-671) to Treat Chronic Gout and Hyperuricemia
PRESS RELEASE...
12 November, 2024
Atom Therapeutics to Present Positive Data from a Phase 1 Trial of Its Novel URAT1 Inhibitor for Chronic Gout (ABP-671) in Participants with Chronic Kidney Disease at ACR Convergence 2024
PRESS RELEASE...
12 November, 2024
Atom Bioscience Changes Name to Atom Therapeutics To Better Reflect Focus on Development of Best-in-Class Novel Oral Drugs for Inflammatory and Metabolic Diseases
PRESS RELEASE...
21 May, 2024
Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the Cause of Gout
PRESS RELEASE...
More Atom News